Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.03
BAX's Cash-to-Debt is ranked lower than
57% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BAX: 1.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: N/A
Current: 1.03
Equity-to-Asset 0.56
BAX's Equity-to-Asset is ranked lower than
58% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BAX: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
BAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.37 Max: 0.56
Current: 0.56
0.22
0.56
Interest Coverage 11.58
BAX's Interest Coverage is ranked lower than
75% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. BAX: 11.58 )
Ranked among companies with meaningful Interest Coverage only.
BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.4 Max: 32.02
Current: 11.58
3.08
32.02
Piotroski F-Score: 6
Altman Z-Score: 5.43
Beneish M-Score: -2.95
WACC vs ROIC
6.18%
8.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 8.57
BAX's Operating Margin % is ranked higher than
57% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. BAX: 8.57 )
Ranked among companies with meaningful Operating Margin % only.
BAX' s Operating Margin % Range Over the Past 10 Years
Min: 4.5  Med: 17.94 Max: 22.9
Current: 8.57
4.5
22.9
Net Margin % 18.09
BAX's Net Margin % is ranked higher than
99% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. BAX: 18.09 )
Ranked among companies with meaningful Net Margin % only.
BAX' s Net Margin % Range Over the Past 10 Years
Min: 9.71  Med: 16.5 Max: 48.85
Current: 18.09
9.71
48.85
ROE % 21.50
BAX's ROE % is ranked higher than
98% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. BAX: 21.50 )
Ranked among companies with meaningful ROE % only.
BAX' s ROE % Range Over the Past 10 Years
Min: 11.41  Med: 30.38 Max: 57.95
Current: 21.5
11.41
57.95
ROA % 11.56
BAX's ROA % is ranked higher than
98% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. BAX: 11.56 )
Ranked among companies with meaningful ROA % only.
BAX' s ROA % Range Over the Past 10 Years
Min: 4.11  Med: 11.59 Max: 27.2
Current: 11.56
4.11
27.2
ROC (Joel Greenblatt) % 35.02
BAX's ROC (Joel Greenblatt) % is ranked higher than
94% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. BAX: 35.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.65  Med: 39.84 Max: 91.88
Current: 35.02
5.65
91.88
3-Year Revenue Growth Rate 2.50
BAX's 3-Year Revenue Growth Rate is ranked lower than
55% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BAX: 2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 2.8 Max: 17.3
Current: 2.5
-17.6
17.3
3-Year EBITDA Growth Rate 71.00
BAX's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. BAX: 71.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: 2.9 Max: 71
Current: 71
-28.3
71
3-Year EPS without NRI Growth Rate 151.00
BAX's 3-Year EPS without NRI Growth Rate is ranked higher than
98% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BAX: 151.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 169.6
Current: 151
-44
169.6
GuruFocus has detected 10 Warning Signs with Baxter International Inc $BAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BAX Guru Trades in Q2 2016

John Hussman 175,000 sh (New)
Leucadia National 700,000 sh (New)
Lee Ainslie 73,700 sh (New)
First Eagle Investment 2,129,733 sh (+193512.09%)
Jim Simons 583,200 sh (+12.80%)
Jeremy Grantham 36,465 sh (+11.88%)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
John Buckingham Sold Out
David Einhorn Sold Out
Tweedy Browne Global Value 1,055,212 sh (-3.62%)
Daniel Loeb 51,901,767 sh (-3.62%)
Tweedy Browne 2,393,665 sh (-3.97%)
Mairs and Power 1,948,504 sh (-4.29%)
Keeley Asset Management Corp 58,610 sh (-4.70%)
Mario Gabelli 125,100 sh (-18.63%)
Richard Pzena 3,115,865 sh (-23.71%)
George Soros 284,327 sh (-36.56%)
Vanguard Health Care Fund 7,053,480 sh (-36.89%)
Joel Greenblatt 849,128 sh (-49.91%)
Paul Tudor Jones 27,459 sh (-57.55%)
Charles Brandes 75,584 sh (-75.67%)
Steven Cohen 3,600 sh (-92.94%)
» More
Q3 2016

BAX Guru Trades in Q3 2016

Steven Cohen 227,300 sh (+6213.89%)
First Eagle Investment 2,635,577 sh (+23.75%)
Paul Tudor Jones 33,174 sh (+20.81%)
John Hussman 200,000 sh (+14.29%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Jeremy Grantham Sold Out
Charles Brandes Sold Out
Leucadia National Sold Out
Mario Gabelli 123,500 sh (-1.28%)
Keeley Asset Management Corp 57,410 sh (-2.05%)
Mairs and Power 1,903,688 sh (-2.30%)
Lee Ainslie 67,360 sh (-8.60%)
Tweedy Browne 2,157,391 sh (-9.87%)
George Soros 254,327 sh (-10.55%)
Joel Greenblatt 638,063 sh (-24.86%)
Vanguard Health Care Fund 4,902,940 sh (-30.49%)
Richard Pzena 1,061,577 sh (-65.93%)
Jim Simons 158,000 sh (-72.91%)
» More
Q4 2016

BAX Guru Trades in Q4 2016

Bill Nygren 4,600,000 sh (New)
Joel Greenblatt 1,271,879 sh (+99.33%)
Lee Ainslie 71,400 sh (+6.00%)
John Hussman 202,300 sh (+1.15%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Steven Cohen Sold Out
Tweedy Browne 2,150,819 sh (-0.30%)
Paul Tudor Jones 32,911 sh (-0.79%)
Murray Stahl 13,922 sh (-1.42%)
Mario Gabelli 120,900 sh (-2.11%)
Mairs and Power 1,752,525 sh (-7.94%)
George Soros 184,327 sh (-27.52%)
Vanguard Health Care Fund 3,094,340 sh (-36.89%)
Jim Simons 64,100 sh (-59.43%)
Keeley Asset Management Corp 21,474 sh (-62.60%)
Richard Pzena 225,790 sh (-78.73%)
First Eagle Investment 1,100 sh (-99.96%)
» More
Q1 2017

BAX Guru Trades in Q1 2017

Jeremy Grantham 74,400 sh (New)
Steven Cohen 633,448 sh (New)
Caxton Associates 10,900 sh (New)
Jim Simons 1,897,115 sh (+2859.62%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Tom Gayner 22,000 sh (unchged)
First Eagle Investment 1,100 sh (unchged)
Vanguard Health Care Fund 3,094,340 sh (unchged)
Richard Pzena Sold Out
George Soros Sold Out
Murray Stahl 13,822 sh (-0.72%)
Mario Gabelli 119,600 sh (-1.08%)
Mairs and Power 1,631,800 sh (-6.89%)
Daniel Loeb 46,000,000 sh (-11.37%)
Joel Greenblatt 1,017,461 sh (-20.00%)
Paul Tudor Jones 25,876 sh (-21.38%)
Lee Ainslie 55,790 sh (-21.86%)
Tweedy Browne 1,559,436 sh (-27.50%)
John Hussman 102,300 sh (-49.43%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:ESLOY, NAS:ILMN, NYSE:BDX, NYSE:BCR, OTCPK:CLPBY, NYSE:MTD, OTCPK:TRUMF, NAS:XRAY, NYSE:WAT, OTCPK:OCPNY, NAS:HOLX, NYSE:COO, NYSE:RMD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, OTCPK:GNGBF, NYSE:HRC, NYSE:CMD, NAS:ICUI » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Headquarter Location:USA
Baxter International Inc provides renal and hospital products including acute and chronic dialysis, sterile IV solutions, infusion systems and systems, parenteral nutrition therapies, biosurgery products and anesthetics, drug reconstitution systems etc.

Baxter manufactures medical products across four major business segments. The renal segment (38% of sales) includes hemodialysis and peritoneal dialysis products. Integrated pharmacy solutions (23% of sales) includes nutrition, injectable drugs, and compounding services. IV pumps and solutions make up the fluid systems segment (21% of sales), while biosurgical supplies and anesthetic gases constitute the surgical care segment (13% of sales). Contract manufacturing services round out the roughly remaining 4% of sales.

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Baxter International Inc

Bill Nygren Comments on Baxter Guru stock highlight
Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value. Read more...
Vanguard Health Care Fund Sells Amgen, Baxter The guru's largest 3rd-quarter sales
Following its third-quarter report, Vanguard Health Care Fund (Trades, Portfolio) holds 73 stocks with a total value of $46.245 billion. The following are the sales with the largest impacts on its portfolio. Read more...
Medical Companies Offer Good Value Opportunities A discussion of Peter Lynch, his top-performing strategies and good health care companies
Due to the great financial crisis, most companies were undervalued based on their valuations. Based on backtesting results, the “Peter Lynch Growth with Lower Valuation” test portfolio took positions in Baxter International Inc. (NYSE:BAX) and Abbott Laboratories (NYSE:ABT), two medical companies that reached historically low price-earnings ratios. While these companies presented good value opportunities from 2007-2011, other medical companies provide better opportunities in 2016. Read more...

Ratios

vs
industry
vs
history
PE Ratio 17.35
BAX's PE Ratio is ranked higher than
97% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. BAX: 17.35 )
Ranked among companies with meaningful PE Ratio only.
BAX' s PE Ratio Range Over the Past 10 Years
Min: 4.88  Med: 9.45 Max: 22.53
Current: 17.35
4.88
22.53
Forward PE Ratio 26.81
BAX's Forward PE Ratio is ranked lower than
53% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. BAX: 26.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.40
BAX's PE Ratio without NRI is ranked higher than
97% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. BAX: 17.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.89  Med: 10.1 Max: 115.67
Current: 17.4
4.89
115.67
Price-to-Owner-Earnings 17.78
BAX's Price-to-Owner-Earnings is ranked higher than
95% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. BAX: 17.78 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.31  Med: 11.74 Max: 39.39
Current: 17.78
5.31
39.39
PB Ratio 3.66
BAX's PB Ratio is ranked higher than
52% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. BAX: 3.66 )
Ranked among companies with meaningful PB Ratio only.
BAX' s PB Ratio Range Over the Past 10 Years
Min: 2.06  Med: 2.65 Max: 3.69
Current: 3.66
2.06
3.69
PS Ratio 3.15
BAX's PS Ratio is ranked higher than
54% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. BAX: 3.15 )
Ranked among companies with meaningful PS Ratio only.
BAX' s PS Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.59 Max: 3.17
Current: 3.15
1.06
3.17
Price-to-Free-Cash-Flow 21.27
BAX's Price-to-Free-Cash-Flow is ranked lower than
52% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. BAX: 21.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.94  Med: 10.08 Max: 54.26
Current: 21.27
6.94
54.26
Price-to-Operating-Cash-Flow 14.84
BAX's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. BAX: 14.84 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.57  Med: 7.23 Max: 18.88
Current: 14.84
4.57
18.88
EV-to-EBIT 15.67
BAX's EV-to-EBIT is ranked higher than
98% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. BAX: 15.67 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.5 Max: 63.8
Current: 15.67
-2940.9
63.8
EV-to-EBITDA 11.22
BAX's EV-to-EBITDA is ranked higher than
99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. BAX: 11.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.1  Med: 6.8 Max: 45.7
Current: 11.22
4.1
45.7
Shiller PE Ratio 13.83
BAX's Shiller PE Ratio is ranked higher than
96% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. BAX: 13.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.74  Med: 12.81 Max: 21.84
Current: 13.83
9.74
21.84
Current Ratio 2.72
BAX's Current Ratio is ranked lower than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. BAX: 2.72 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.65 Max: 2.72
Current: 2.72
1.08
2.72
Quick Ratio 2.11
BAX's Quick Ratio is ranked higher than
58% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. BAX: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.05 Max: 2.11
Current: 2.11
0.74
2.11
Days Inventory 93.12
BAX's Days Inventory is ranked higher than
68% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. BAX: 93.12 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 91.48  Med: 138.8 Max: 219.03
Current: 93.12
91.48
219.03
Days Sales Outstanding 58.54
BAX's Days Sales Outstanding is ranked lower than
65% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. BAX: 58.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 66.28 Max: 112.88
Current: 58.54
58.53
112.88
Days Payable 47.52
BAX's Days Payable is ranked lower than
53% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. BAX: 47.52 )
Ranked among companies with meaningful Days Payable only.
BAX' s Days Payable Range Over the Past 10 Years
Min: 39.5  Med: 46.3 Max: 76.67
Current: 47.52
39.5
76.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.89
BAX's Dividend Yield % is ranked lower than
61% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BAX: 0.89 )
Ranked among companies with meaningful Dividend Yield % only.
BAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.88  Med: 3.81 Max: 5.89
Current: 0.89
0.88
5.89
Dividend Payout Ratio 0.15
BAX's Dividend Payout Ratio is ranked higher than
99% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BAX: 0.15 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.35 Max: 3.37
Current: 0.15
0.06
3.37
3-Year Dividend Growth Rate -35.90
BAX's 3-Year Dividend Growth Rate is ranked lower than
86% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. BAX: -35.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: 6.3 Max: 22.5
Current: -35.9
-35.9
22.5
Forward Dividend Yield % 1.09
BAX's Forward Dividend Yield % is ranked lower than
66% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. BAX: 1.09 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.42
BAX's 5-Year Yield-on-Cost % is ranked lower than
69% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. BAX: 0.42 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.42  Med: 1.82 Max: 2.82
Current: 0.42
0.42
2.82
3-Year Average Share Buyback Ratio 0.20
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. BAX: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: -0.4 Max: 3.3
Current: 0.2
-5.1
3.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.40
BAX's Price-to-Tangible-Book is ranked lower than
59% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. BAX: 6.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.11  Med: 5.01 Max: 18.21
Current: 6.4
2.11
18.21
Price-to-Intrinsic-Value-Projected-FCF 1.39
BAX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. BAX: 1.39 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 2.71
Current: 1.39
0.52
2.71
Price-to-Median-PS-Value 1.98
BAX's Price-to-Median-PS-Value is ranked lower than
78% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. BAX: 1.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 2.14
Current: 1.98
0.19
2.14
Price-to-Graham-Number 2.23
BAX's Price-to-Graham-Number is ranked higher than
78% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. BAX: 2.23 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.76  Med: 1.53 Max: 7
Current: 2.23
0.76
7
Earnings Yield (Greenblatt) % 6.38
BAX's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. BAX: 6.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.6 Max: 20.9
Current: 6.38
1.6
20.9
Forward Rate of Return (Yacktman) % 6.91
BAX's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. BAX: 6.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.8  Med: 15.7 Max: 30
Current: 6.91
-11.8
30

More Statistics

Revenue (TTM) (Mil) $10,263
EPS (TTM) $ 3.38
Beta0.76
Short Percentage of Float1.45%
52-Week Range $42.22 - 59.41
Shares Outstanding (Mil)543.67

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,259 10,659 11,056
EPS ($) 2.19 2.47 2.75
EPS without NRI ($) 2.19 2.47 2.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.39%
Dividends per Share ($) 0.54 0.59 0.67
» More Articles for BAX

Headlines

Articles On GuruFocus.com
5 Companies Reach Yearly Highs May 03 2017 
Daniel Loeb’s Value-Seeking Journey Apr 30 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter Internationa Apr 19 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter Internati Apr 17 2017 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Apr 11 2017 
10 Low PE Stock Picks for Value Investors Mar 28 2017 
10 Low PE Stock Picks for Defensive Investors Feb 27 2017 
10 Undervalued Companies for Value Investors Feb 14 2017 
Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017 
Using a Benjamin Graham Value Investing Strategy Feb 07 2017 

More From Other Websites
Tweedy Browne Sells Baxter, Cisco, 3M May 25 2017
Medtronic's focus on surgical products fuels profit beat May 25 2017
Zacks.com featured highlights: Applied Materials, Coherent, Axcelis Technologies, Baxter... May 25 2017
Fed balance sheet unwind 'absolutely' reduces chance of more rate hikes: Former Dallas Fed... May 24 2017
New Strong Buy Stocks for May 24th May 24 2017
Can These 3 High-Flying Healthcare Stocks Reach the Clouds? May 23 2017
Alexion stock plummets 9% after top management shake-up May 23 2017
Baxter Presents Data at ISPOR Annual Meeting with Focus on Helping Hospitals Improve Patient Care May 23 2017
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM... May 22 2017
Quest Diagnostics Poised on Solid Q1 Results Despite Woes May 22 2017
Baxter International Inc. -- Moody's rates Baxter's new euro notes Baa2; stable outlook May 19 2017
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint May 19 2017
Commonwealth Fund President, David Blumenthal, MD, MPP, Named 2017 Recipient of the William B.... May 19 2017
Baxter to Present at the Goldman Sachs 38th Annual Healthcare Conference May 18 2017
Baxter Launches New AK 98 Hemodialysis System Designed to Help Providers Reach Treatment Goals May 18 2017
Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive May 17 2017
Yum Brands, Intuitive Surgical Called Buys; Pfizer Cut To Sell May 16 2017
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1 May 15 2017
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up May 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)